Last $6.44 USD
Change Today +0.04 / 0.63%
Volume 65.6K
MDGN On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc - unrestricted (MDGN) Snapshot

Open
$6.46
Previous Close
$6.40
Day High
$6.60
Day Low
$6.42
52 Week High
02/12/14 - $9.00
52 Week Low
08/28/13 - $3.87
Market Cap
120.5M
Average Volume 10 Days
28.3K
EPS TTM
--
Shares Outstanding
18.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDGENICS INC - UNRESTRICTED (MDGN)

Related News

No related news articles were found.

medgenics inc - unrestricted (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc - unrestricted (MDGN) Details

Medgenics, Inc., a medical technology and therapeutics company, is engaged in the research and development of products in the field of biotechnology and associated medical equipment in the United States. The company develops and commercializes Biopump platform technology that converts a piece of the patient’s own dermal skin tissue into a protein- and/or peptide-producing ‘Biopump’ to produce and deliver therapeutic proteins and/or peptides, and—when implanted under the patient’s skin—has the potential to deliver various months of protein/peptide therapy. Its product candidates include EPODURE Biopump, which is in Phase I/II clinical trials for the treatment of anemia in CKD and renal failure; and HEMODURE Biopump, which is under pre-clinical studies and produces Factor VIII for the treatment of patients with hemophilia. The company also develops INFRADURE Biopump that produces interferon-alpha for the treatment of patients with hepatitis C. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

36 Employees
Last Reported Date: 02/20/14
Founded in 2000

medgenics inc - unrestricted (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $226.1K
Chief Financial Officer
Total Annual Compensation: $216.2K
Global Head of Research and Development
Total Annual Compensation: $193.9K
Compensation as of Fiscal Year 2013.

medgenics inc - unrestricted (MDGN) Key Developments

Medgenics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Medgenics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported operating loss of $8,872,000 against $7,020,000 a year ago. Financial income was $18,000 against $1,286,000 a year ago. The decrease was primarily due to the change in valuation of the warrant liability. Loss before taxes on income was $9,191,000 against $5,773,000 a year ago. Loss was $9,197,000 or $0.49 per basic and diluted share against $5,778,000 or $0.42 per diluted share a year ago. The company isn't generating any revenue yet. For the six months, the company reported operating loss of $3,637,000 against $2,443,000 a year ago. Financial income was $15,000 against $371,000 a year ago. The decrease was primarily due to the change in valuation of the warrant liability. Loss before taxes on income was $3,839,000 against $2,097,000 a year ago. Loss was $3,840,000 or $0.21 per basic and diluted share against $2,099,000 or $0.11 per diluted share a year ago.

Medgenics, Inc. Presents at Piper Jaffray GenomeRx Symposium, Jun-23-2014 02:35 PM

Medgenics, Inc. Presents at Piper Jaffray GenomeRx Symposium, Jun-23-2014 02:35 PM. Venue: Yale Club, New York, New York, United States. Speakers: Garry A. Neil, Global Head of Research and Development.

Medgenics, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:00 PM

Medgenics, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 03:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $6.44 USD +0.04

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies
 

Industry Analysis

MDGN

Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC - UNRESTRICTED, please visit www.medgenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.